- The Court of Tax Appeals ordered the Bureau of Internal Revenue to pay AstraZeneca ₱37.15 million or issue a tax credit.
- The ruling was due to illegal VAT collection on imported medicines exempt under Philippine law.
- The case involved drugs for diabetes, high cholesterol, and hypertension imported in 2020.
- AstraZeneca initially sought a refund of ₱42.47 million, but some medicines were not VAT exempt.
- The court confirmed AstraZeneca filed on time and followed all procedures.
- A ₱1.92-million discrepancy was attributed to mixed shipments.
- VAT exemptions for certain medicines began on January 1, 2020, under Republic Act 11467.
Source: bilyonaryo.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
Latest Posts in "Philippines"
- The BIR suspends audits of books of accounts until further notice
- Philippine Senate Proposes Abolishing VAT and 3% Tax, Signaling Major Tax Reform
- Philippine Court Clarifies Input VAT Refunds for Zero-Rated Sales in Recent Decision
- Philippine Court Bars VAT Deficiency Collection Due to Expired Three-Year Prescriptive Period
- Philippine Court Clarifies Input VAT Refunds for Zero-Rated Sales in Multinational Branch Case
